Biota to boost Melbourne facilities
21 March, 2012 by Dylan Bushell-EmblingBiota (ASX:BTA) will expand its facilities in Melbourne to allow it to fulfil a $220m contract for the advanced development of a influenza antiviral in the US.
Patrys publishes PAT-SM6 trial results
20 March, 2012 by Dylan Bushell-EmblingMelbourne's Patrys Limited (ASX:PAB) has published the results of a safety and tolerability trial of anti-cancer antibody PAT-SM6.
Launch of the CEO survey at April member-only briefings
20 March, 2012 by AusBiotechAusBiotech’s 2012 CEO Biotechnology Industry Position Survey will be launched by AusBiotech’s CEO, Dr Anna Lavelle, at the member-only briefings in April.
Pharmaxis to get PBS tick for Bronchitol
20 March, 2012 by Tim DeanPharmaxis’ cystic fibrosis treatment Bronchitol is slated to be listed on the Pharmaceutical Benefits Scheme for reimbursement.
Vale Andrew Baker
20 March, 2012 by Staff WritersBiotechnology and pharmaceutical industry veteran and GBS Ventures partner, Dr Andrew Baker, died on Sunday March 18 from cancer.
REVA Medical gets major new investors
20 March, 2012 by Dylan Bushell-EmblingA group of buyers including Elliott Management have purchased $23m worth of CDIs and shares in ASX-listed US medical device company REVA Medical (ASX:RVA).
QRxPharma signs licensing deal with Actavis
20 March, 2012 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has closed a deal to license its dual-opioid pain product, MoxDuo IR, to pharmaceutical company Actavis.
Bioniche secures $19m finance facility
19 March, 2012 by Dylan Bushell-EmblingDual-listed biotech Bioniche (ASX:BNC) has negotiated to receive a $19m, non-dilutive finance facility from the USA's Capital Royalty.
LBT Innovations applies for APAS patents
16 March, 2012 by Dylan Bushell-EmblingLBT Innovations (ASX:LBT) has filed applications for international patents for its second invention, the Automated Plate Assessment System (APAS).
Pharmaxis close to EU approval for Bronchitol
16 March, 2012 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has been notified that it should soon receive approval for its marketing application to sell its Bronchitol cystic fibrosis treatment in the EU.
Prima BioMed gets TGA nod to manufacture CVac
15 March, 2012 by Dylan Bushell-EmblingThe TGA has granted manufacturing approval for Prima BioMed (ASX:PRR) to produce its CVac ovarian cancer vaccine in Australia, for use in a major clinical trial.
IQnovate signs first deal since NSX listing
15 March, 2012 by Dylan Bushell-EmblingContract medical company IQnovate (NSX:IQN) has signed a preliminary agreement to provide commercialisation services for JH Biotech Australasia.
Phosphagenics signs skincare deal in Korea
15 March, 2012 by Dylan Bushell-EmblingDrug delivery company Phosphagenics (ASX:POH) has secured an agreement to supply its BioElixia skincare products to a Korean distributor.
BioPro survey to see what’s hot in professional development
15 March, 2012 by AusBiotechAusBiotech’s biotechnology-specific professional development program is running an express survey to see if it is meeting your professional development needs.
Celxel implants CardioCel in valve reconstructs
13 March, 2012 by Dylan Bushell-EmblingAllied Healthcare's (ASX:AHZ) tissue engineering division has implanted its CardioCel patch in heart valve reconstructions, during a phase I animal trial.
